Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bangkok Genomics Innovation PCLBKK:BKGI -0.82%45 Debt-to-EBITDA is 0.12 as of Jun. 2026, which is 65% below its 10-year median of 0.34. GuruFocus rates BKK:BKGI with a GF Score™ of 45/100. The stock has 9 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Bangkok Genomics Innovation PCL ranks better than 87.18% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Bangkok Genomics Innovation PCL's Debt-to-EBITDA or its related term are showing as below:
BKK:BKGI'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.09 Med: 0.34 Max: 0.61
Current: 0.22
During the past 7 years, the highest Debt-to-EBITDA Ratio of Bangkok Genomics Innovation PCL was 0.61. The lowest was 0.09. And the median was 0.34.
BKK:BKGI's Debt-to-EBITDA is ranked better than 87.18% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.52
vs BKK:BKGI: 0.22
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Bangkok Genomics Innovation PCL Debt-to-EBITDA Related Terms
Bangkok Genomics Innovation PCL Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:BKGI vs TMO, DHR, NTRA: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Genomics Innovation PCL Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bangkok Genomics Innovation PCL's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Bangkok Genomics Innovation PCL (BKK:BKGI) has a Debt-to-EBITDA of 0.12 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bangkok Genomics Innovation PCL. This is 65% below median its historical median of 0.34. Over the past decade, Bangkok Genomics Innovation PCL's Debt-to-EBITDA has ranged from 0.09 to 0.61. According to the industry distribution chart, Bangkok Genomics Innovation PCL ranks #15 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 12.8%.
Is Bangkok Genomics Innovation PCL's Debt-to-EBITDA too high?
Bangkok Genomics Innovation PCL's current Debt-to-EBITDA of 0.12 is 65% below median its 10-year median of 0.34. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 0.61. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.52. Bangkok Genomics Innovation PCL's value of 0.12 is 95.2% below this industry median. Based on the distribution chart, Bangkok Genomics Innovation PCL ranks #15 out of 117 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bangkok Genomics Innovation PCL ranks #15 out of 117 companies for Debt-to-EBITDA. This places Bangkok Genomics Innovation PCL in the top 13% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.52. Bangkok Genomics Innovation PCL's value of 0.12 is 95.2% below this benchmark. Historically, Bangkok Genomics Innovation PCL's own Debt-to-EBITDA has ranged from 0.09 to 0.61 over the past decade. While the company's 10-year median is 0.34 vs. the industry median of 2.52, Bangkok Genomics Innovation PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.52, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bangkok Genomics Innovation PCL's current Debt-to-EBITDA of 0.12 is 95.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bangkok Genomics Innovation PCL. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bangkok Genomics Innovation PCL's current Debt-to-EBITDA is 0.12, which is 65% below median its own 10-year median of 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current Debt-to-EBITDA of 0.12. The current Debt-to-EBITDA is 0.12, which is 65% below median its 10-year median of 0.34 and 95.2% below the Medical Diagnostics & Research industry median of 2.52. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current Debt-to-EBITDA is 0.12 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score
Get the complete analysis for BKK:BKGI
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BKGI has been successfully added to your 
